Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
P/E ratio for iTeos Therapeutics, Inc. (ITOS)
P/E ratio as of 2023: -3.48
According to iTeos Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.48. At the end of 2022 the company had a P/E ratio of 7.18.
P/E ratio history for iTeos Therapeutics, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -3.48 |
| 2022 | 7.18 |
| 2021 | 7.64 |
| 2020 | -31.16 |
| 2019 | -29.71 |
| 2018 | -7.92 |